Quetiapine augmentation outperforms lithium augmentation in long-term clinical and cost-effectiveness among adults with ...

Quetiapine (Seroquel) was more clinically effective than lithium as a first-line augmentation option in treatment-resistant depression and likely was more cost-effective, a pragmatic multicenter ...

Therefore, the convenient dosage regimen and rapid initiation scheme of quetiapine extended release (XR) were expected to provide better effectiveness and promote adherence in patients with ...

In the ESCAPE-TRD study, Spravato outperformed quetiapine on the main endpoint of achieving remission at eight weeks, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with rates ...

Augmentation was more effective with quetiapine than lithium for treatment-resistant depression in a pragmatic trial. Quetiapine also improved quality-adjusted life years more than lithium.